Genentech: David Hackos | Senior Scientist, Neuroscience

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/david-hackos

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"My passion is to do great science that will someday result in innovative new medicines that will make patient's lives better."

Years at Genentech

Publications

Awards & Honors

Ever since I was a graduate student at the University of California San Francisco, I have been fascinated by the structure, function, and pharmacology of ion channels. These critical proteins form the functional basis of the nervous system, and without them, our neurons would not be able to send signals down their axons or communicate with each other through synaptic transmission. Despite their importance in physiology, ion channels also make excellent drug targets for a variety of neurological disorders, as long as we can figure out how to target them selectively and in the right way. Currently my lab is leading efforts in the development of novel pain drugs that take advantage on ion channels as targets.

Postdoctoral Mentor

Genentech is a place where you can do science at the highest possible level within a highly multi-disciplinary research environment with cutting-edge infrastructure. The postdoc program at Genentech provides a place for young scientists to dive into this environment and make fundamental contributions to our understanding of the biology of neurological disorders, laying the groundwork for the discovery of the next generation of high-impact therapeutics.

Featured Publication

Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function.

Neuron. 2016 Mar 2;89(5):983-99.

Hackos DH, Lupardus P, Wang TM, Chen Y, Reynen P, Gustafson A, Wallweber HA, Volgraf M, Sellers B, Schwarz J, Zhou Q, Paoletti P, Sheng M, Hanson JE.

View Abstract

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.

Science. 2015 Dec 18;350(6267):aac5464.

Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez JC, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J.

View Abstract

One major focus of my lab is the development of selective voltage-gated sodium channel modulators. Our work on Nav1.7, an important pain target, has led to the discovery of a novel binding site that allows the development of highly isoform-selective sodium channel blockers that some day might lead to a revolutionary new type of pain drug. Another focus has been on selective positive allosteric modulators of NMDA receptors, which could lead to new drugs for epilepsy, schizophrenia, or Alzheimer's disease. Also, our work on the human genetics of pain and studies of the circuitry of pain within the spinal cord are yielding new mechanistic insights that may lead to novel ways to target pain in the future.

Behavioral characterization of a CRISPR-generated TRPA1 knockout rat in models of pain, itch, and asthma

Scientific Reports, ISSN: 20452322

Rebecca M. Reese; Michelle Dourado; Keith Anderson; Soren Warming; Kimberly L. Stark; Alessia Balestrini; Eric Suto; Wyne Lee; Lorena Riol Blanco; Shannon Shields; David Hackos

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

David Hackos

Senior Scientist, Neuroscience

Featured Publication

Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function.

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.